BioLineRx Ltd. (NASDAQ:BLRX) Sees Significant Decrease in Short Interest

BioLineRx Ltd. (NASDAQ:BLRX) saw a large decrease in short interest in the month of December. As of December 15th, there was short interest totalling 827,800 shares, a decrease of 10.2% from the November 30th total of 921,900 shares. Based on an average trading volume of 1,000,000 shares, the short-interest ratio is presently 0.8 days.

BioLineRx Price Performance

Shares of NASDAQ:BLRX traded up $0.00 during trading hours on Wednesday, hitting $0.21. 1,393,354 shares of the company’s stock traded hands, compared to its average volume of 529,682. The company’s fifty day simple moving average is $0.33 and its two-hundred day simple moving average is $0.53. The company has a market cap of $17.11 million, a price-to-earnings ratio of -0.97 and a beta of 1.39. The company has a debt-to-equity ratio of 2.11, a quick ratio of 1.37 and a current ratio of 1.52. BioLineRx has a 52 week low of $0.19 and a 52 week high of $1.59.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on BLRX. HC Wainwright lowered their price objective on shares of BioLineRx from $21.00 to $9.00 and set a “buy” rating on the stock in a research note on Monday, November 25th. StockNews.com started coverage on BioLineRx in a research report on Thursday, December 26th. They set a “hold” rating on the stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in BLRX. PVG Asset Management Corp acquired a new stake in shares of BioLineRx during the 2nd quarter valued at $70,000. Atria Investments Inc lifted its holdings in shares of BioLineRx by 27.9% during the third quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock valued at $72,000 after purchasing an additional 29,193 shares during the last quarter. Finally, CVI Holdings LLC purchased a new stake in shares of BioLineRx during the second quarter valued at $462,000. Institutional investors and hedge funds own 1.56% of the company’s stock.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.